Q-linea
Business Services · Sweden · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Dag Hammarskjölds Väg 52 a, Uppsala, Upp...Phone Number
+46 184443610Website
www.qlinea.comRevenue
<$5 MillionStock Symbol
QLINEAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Q-linea
Q-linea AB is a medical technology company that develops advanced diagnostic solutions aimed at improving the management of infectious diseases in clinical settings. It focuses on enabling faster and more accurate identification of pathogens and their response to antimicrobial treatments through specialized instruments and consumables. By supporting timely and precise therapeutic decisions, the company helps healthcare providers enhance patient care, address challenges related to antibiotic resistance, and streamline laboratory workflows in hospitals and diagnostic environments.Explore more
Q-linea Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Q-linea your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Q-linea has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Q-linea
Product Launch: Get notified when Q-linea launches new products
Q-linea, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Q-linea had a recent Job posting/layoffs
Check out if Q-linea is spiking on competitors!
Earning: See what the market has to say on Q-linea recently announced quarterly report
Funding: Get notified immidiatlly once Q-linea has new funding data
Recommended Actions
Find VP level buyers at Q-linea
Find 3 more new buyers
Company Profile Activity
Activity Insights
Q-linea is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Q-linea is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Q-linea.
Q-linea Tech Stack
A closer look at the technologies used by Q-linea
See more technologies
Most Recent Scoops
Partnership
Q-linea has partnered with Amico in the Greater Gulf region, which has close connections across countries in that region. The partnership has resulted in several successfully completed evaluations that are expected to move into contracting and deployment.
Partnership, Sales, Business Development
Event
leadership presented at IDWeek in Q4 2025 in Atlanta and at AMARI in Las Vegas in early 2026, engaging with key opinion leaders and stakeholders in intimate settings.
Events, Customer Engagement, Communications, Marketing Communications
Pain Point
Q-linea was disappointed by the adjudication of the ESTAR tender for 9 units in Italy. The company has placed very low visibility on these units, though the process remains somewhat open.
Pain Point, Sales, Contracts
Pain Point
fell short of its 2025 plan primarily in the US market due to the initial FDA-cleared menu being smaller than the European menu, attributed to technical requirements of the R&D clinical trial.
Pain Point, Sales, Compliance
Project
Sales, Forecasting
Q-linea News & Media
Invitation to presentation of Q-linea’s Interim report Q3-2020 on November 5, 2020
Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – September 2020 on Thursday, November 5, 2020 at 07:30 a.m. CET. Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on November 5, 2020, at 1:00 – 2:00 p.m CET. Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Q3 interim report followed by a Q&A-session. ToWebinar Tuesday November 10th: Equal and better care for everyone
Q-linea AB (publ) (OMX: QLINEA), invites you to a webinar with presentations followed by a Q&A session by CEO Jonas Jarvius, Research Director Mats Gullberg and Marketing & Sales Director Charlotta Göransson. Date: November 10th Time: 17.00 CET, 11 AM EDT, 8 AM PDT Duration: 1 hour On the agenda: · How ASTar meets the challenges in the lab and clinic, and help improve patient outcomes · Sneak peek on an upcoming exciting product ·Q-linea enters into an agreement with Hvidovre Hospital as a participant in the clinical study
Q-linea AB (publ) (OMX:QLINEA), today announced that Hvidovre Hospital in Denmark will participate in the company's European pivotal clinical study, which will start in the autumn of 2020. Through the choice of Hvidovre Hospital, Q-linea has now chosen the sites required to be able to start the prospective performance study with 80 to 100 patients during the autumn of 2020. The study will take place internally at Q-linea, at Hvidovre Hospital and at Uppsala UniversityQ-linea installs the first ASTar system at Uppsala University Hospital
Q-linea AB (publ) (OMX: QLINEA), today announced that an ASTar® instrument is now being used for beta testing at Uppsala University Hospital and that the hospital will participate in the company's European pivotal clinical study. Following this spring's collaboration with the laboratory for clinical microbiology at Uppsala University Hospital, Q-linea has now installed an ASTar instrument for evaluation at the hospital for the upcoming pivotal clinical study. “It is an important step for us that
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Q-linea
Sign Up For FreeTo access detailed company insights
Q-linea AB is a medical technology company that develops advanced diagnostic solutions aimed at improving the management of infectious diseases in clinical settings. It focuses on enabling faster and more accurate identification of pathogens and their response to antimicrobial treatments through specialized instruments and consumables. By supportin... Read More
